An open-label, extension, phase III study to evaluate the long-term safety, efficacy and PK of MRA [tocilizumab] in patients with pJIA [polyarticular juvenile idiopathic arthritis] who participated in study MRA318JP.

Trial Profile

An open-label, extension, phase III study to evaluate the long-term safety, efficacy and PK of MRA [tocilizumab] in patients with pJIA [polyarticular juvenile idiopathic arthritis] who participated in study MRA318JP.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2009

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 29 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Planned end date changed from 1 Jul 2005 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top